Trial Summary
What is the purpose of this trial?Every 1-2 years, the seasonal influenza vaccine composition changes to include updated viruses, yet the precise effects of updating the vaccine remain understudied. Since the vaccine formulation for each season (with a season defined as starting in July and ending the following June) expires on June 30, vaccine formulations cannot be compared head-to-head. Thus, the 2023 and 2024 vaccines have only been compared by analyzing people given the former vaccine in the fall of 2023 and people given the latter vaccine in the fall of 2024, and baseline repertoires may have greatly changed over the course of that year. To that end, the investigators will vaccinate a cohort with the 2023 influenza vaccine between May-June 2024, in order to compare responses between individuals receiving the 2023 vaccine last fall, the 2023 vaccine late in the season (this cohort), and the 2024 vaccine next fall. The investigators will further assess whether the late-season 2023 vaccine primed this cohort to respond better to the standard 2024 vaccine with standard timing (vaccine administered around September-October).
Eligibility Criteria
This trial is for individuals who are interested in helping to compare the effectiveness of different seasonal flu vaccines. There aren't specific inclusion or exclusion criteria provided, but typically participants should be healthy, not have allergies to vaccine components, and must not have received the current season's flu vaccine.Inclusion Criteria
Ability to provide signed informed consent
Weigh at least 85 pounds for whole blood draw
I plan to get the flu shot at the La Jolla Institute for Immunology.
+2 more
Exclusion Criteria
I am infected with HIV, hepatitis B, or hepatitis C.
Received an influenza vaccine in the past year
Has ever had Guillain-Barré syndrome
+6 more
Participant Groups
The study aims to understand how effective the late-season administration of the 2023 influenza vaccine is compared to both its standard timing earlier in fall 2023 and next season's (2024) formulation given at standard times.
1Treatment groups
Experimental Treatment
Group I: Late season influenza vaccineExperimental Treatment1 Intervention
Every participant receives the 2023 influenza vaccine between May-June 2024, and then the 2024 influenza vaccine in September-October 2024. Blood draws are taken at Day 0, 30, and 90 post-vaccination.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
La Jolla Institute for ImmunologyLa Jolla, CA
Loading ...
Who Is Running the Clinical Trial?
Tal EinavLead Sponsor
La Jolla Institute for ImmunologyLead Sponsor